文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

抗血管内皮生长因子药物治疗色素失禁症相关性视网膜病变

[Treatment of retinopathy of incontinentia pigmenti by anti-vascular endothelial growth factor].
PubMed 文献 · Zhonghua Yan Ke Za Zhi · 2019-01-01

回顾性系列病例研究纳入2005至2017年确诊的5例(8只眼)色素失禁症相关性视网膜病变患儿,均为女性,平均就诊年龄2.4个月。患儿接受玻璃体腔注射抗VEGF药物,部分联合激光光凝、玻璃体切除术或视网膜冷冻术及外加压术;至随访日4例(7只眼)视网膜在位。作者初步证实抗VEGF药物治疗有效,但最佳使用时机、剂量和局部及全身安全性问题有待更多研究进一步观察。

要点

  • 5例(8只眼)色素失禁症相关性视网膜病变患儿均接受玻璃体腔注射抗VEGF药物治疗。
  • 注射药物为雷珠单克隆抗体4例(6只眼)或康柏西普1例(2只眼),注射剂量均为0.025 ml。
  • 至随访日4例(7只眼)视网膜在位,2例(2只眼)可见视网膜前增生膜,1例(1只眼)视网膜脱离。

核心结论

  • 初步证实了抗血管内皮生长因子药物在色素失禁症相关性视网膜病变治疗中的有效性。
  • 最佳使用时机、剂量和局部及全身安全性问题有待更多研究进一步观察。

研究设计与样本

  • 回顾性系列病例研究,收集2005至2017年确诊的5例(8只眼)色素失禁症相关性视网膜病变患儿的临床资料。
  • 患儿均为女性,就诊年龄1~5个月,平均2.4个月,详细记录病史及家族史。
  • 5例(10只眼)均行眼前节检查、玻璃体检查、眼底检查和眼压检查,并用Retcam系统行眼底照相,其中2例(4只眼)曾行荧光素眼底血管造影检查。
  • 根据眼底具体情况选择单纯玻璃体腔注药术、玻璃体腔注药术联合激光光凝治疗或玻璃体腔注药术联合玻璃体切除术等,观察术后效果。

主要发现

  • 初诊时视网膜前出血未累及黄斑区3例(5只眼),黄斑区视网膜前出血1例(1只眼),视网膜新生血管3例(5只眼),视网膜脱离2例(2只眼),周边无血管区5例(8只眼)。
  • 视网膜前出血未累及黄斑区5只眼中有3只眼累及视网膜4个象限,2只眼累及颞上、颞上2个象限。
  • 3例(5只眼)单纯玻璃体腔注射抗VEGF药物治疗,1例(1只眼)玻璃体腔注射抗VEGF药物治疗加激光光凝,1例(1只眼)玻璃体腔注射抗VEGF药物治疗加玻璃体切除术,1例(1只眼)玻璃体腔注射抗VEGF药物治疗加视网膜冷冻术及外加压术。
  • 单纯玻璃体腔注射抗VEGF药物治疗患者中2例(3只眼)单次给药,1例(2只眼)多次重复给药。
  • 注射药品选择4例(6只眼)雷珠单克隆抗体(注射剂量0.025 ml),1例(2只眼)康柏西普(注射剂量0.025 ml)。

关键数值与推荐

  • 初诊时周边无血管区5例(8只眼),视网膜新生血管3例(5只眼),视网膜脱离2例(2只眼)。
  • 雷珠单克隆抗体注射剂量0.025 ml用于4例(6只眼),康柏西普注射剂量0.025 ml用于1例(2只眼)。
  • 单纯玻璃体腔注射抗VEGF药物治疗中2例(3只眼)单次给药,1例(2只眼)多次重复给药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 最佳使用时机、剂量和局部及全身安全性问题有待更多研究进一步观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the treatment of retinopathy of incontinentia pigmenti by anti-vascular endothelial growth factor. Methods: Retrospective study of 5 patients(8 eyes) diagnosed retinopathy of incontinentia pigmenti from 2005 to 2017, including 0 males and 5 females (8 eyes involved) with an average age of 2.4 months(range, 1-5 months). Medical history and family history were recorded in detail for all children. We did the examination of anterior segment of the eyeball, vitreous body,fundus and intraocular pressure for the 5 patients(8eyes).What's more,wo also took pictures for fundus with the machine of Retcam. Fundus fluorescence angiography (FFA) was performed in 2 patients(4 eyes). Different surgical methods were selected according to the specific conditions of the eye and postoperative were observed. Results: At the time of initial diagnosis, preretinal hemorrhage did not affect the macular region in 3 cases (5 eyes), pre retinal hemorrhage affected the macular region in 1 case(1 eye), the retinal neovascularization in 3 cases(5 eyes), the retinal detachment in 2 cases(2 eyes), and nonvascular zone of peripheral retinal in 5cases(8 eyes). Treatment and drug selection: 3 cases(5 eyes) were treated with injection anti-VEGF drug into vitreous body cavity, 1 case(1 eye) was treated with injection anti-VEGF drug into vitreous body cavity plus laser photocoagulation, 1 case(1 eye) was treated with anti-VEGF drugs plus vitrectomy. 1 case(1 eye) was treated with anti-VEGF drugs plus retinal cryotherapy and sclera bucking. In patients of injection anti-VEGF drug into vitreous body cavity, 2 cases(3 eyes) were given a single dose and 1 case (2 eyes) was given a repeated dose. Drug selection: 4 cases(6 eyes) ranibizumab injection (injection dose 0.025 ml), 1 case (2 eyes)conbercept injection (injection dose 0.025 ml). To follow-up date, etina was flat in 4 patients (7 eyes), epiretinal membrane in 2 patients(2 eyes), retinal detachment in 1 patient(1 eye). Conclusions: The efficacy of anti-vascular endothelial growth factor in the treatment of retinopathy of incontinentia pigmenti was prelininarily confimed.However,the optimal use timing,dosage,local and systemic safety issues were needed to be further studied. (Chin J Ophthalmol, 2019, 55:294-301). 目的: 探讨色素失禁症相关性视网膜病变的临床表现及抗血管内皮生长因子治疗效果。 方法: 回顾性系列病例研究。收集2005至2017年确诊的5例色素失禁症相关性视网膜病变患儿的临床资料。患儿均为女性,就诊年龄1~5个月,平均2.4个月。详细记录患儿病史及家族史,5例(10只眼)均行眼前节检查、玻璃体检查、眼底检查和眼压检查,并用Retcam系统行眼底照相,其中2例(4只眼)曾行荧光素眼底血管造影检查。根据患儿眼底具体情况选择单纯玻璃体腔注药术、玻璃体腔注药术联合激光光凝治疗或玻璃体腔注药术联合玻璃体切除术等,观察术后效果。 结果: 初诊时视网膜前出血未累及黄斑区3例(5只眼),黄斑区视网膜前出血1例(1只眼),视网膜新生血管3例(5只眼),视网膜脱离2例(2只眼),周边无血管区5例(8只眼)。视网膜前出血未累及黄斑区5只眼中有3只眼累及视网膜4个象限,2只眼累及颞上、颞上2个象限。治疗方案及药物选择:3例(5只眼)单纯玻璃体腔注射抗VEGF药物治疗,1例(1只眼)给予玻璃体腔注射抗VEGF药物治疗加激光光凝,1例(1只眼)给予玻璃体腔注射抗VEGF药物治疗加玻璃体切除术,1例(1只眼)给予玻璃体腔注射抗VEGF药物治疗加视网膜冷冻术及外加压术。在单纯玻璃体腔注射抗VEGF药物治疗患者中有2例(3只眼)单次给药,1例(2只眼)多次重复给药。注射药品选择4例(6只眼)雷珠单克隆抗体(注射剂量0.025 ml),1例(2只眼)康柏西普(注射剂量0.025 ml)。至随访日,4例(7只眼)患儿视网膜在位,2例(2只眼)可见视网膜前增生膜,1例(1只眼)视网膜脱离。 结论: 初步证实了抗血管内皮生长因子药物在色素失禁症相关性视网膜病变治疗中的有效性。但最佳使用时机、剂量和局部及全身安全性问题有待更多研究进一步观察。(中华眼科杂志,2019,55:294-301).

来源:Zhonghua Yan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang X, Liang JH. [Treatment of retinopathy of incontinentia pigmenti by anti-vascular endothelial growth factor]. Zhonghua Yan Ke Za Zhi. 2019. PMID: 30982292. doi:10.3760/cma.j.issn.0412-4081.2019.04.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。